Vanguard Capital Management
BCAB icon

Vanguard Capital Management’s BioAtla BCAB Stock Holding History

Vanguard Capital Management’s Portfolio BCAB Stock Details BCAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$37.9K Sell
9,164
-23,821
-72% -$101K ﹤0.01% 3960
2026
Q1 		$266K Buy
+32,985
New +$386K ﹤0.01% 3764

Other funds holding BCAB

ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
Lido Advisors
Lido Advisors Los Angeles, California $36.8B AUM 26.6% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Capital Management's BCAB Position: Q2 2026 in Review

Vanguard Capital Management reduced its BioAtla (BCAB) stake by 72% in Q2 2026, selling an estimated $101K and leaving 9,164 shares worth $37.9K. The position accounts for ﹤0.01% of the portfolio, ranked #3960.

Vanguard Capital Management first reported a position in BCAB in Q1 2026 and has held it in 2 quarters since. The position peaked at $266K in Q1 2026. 19 funds tracked by Wall St. Rank hold BCAB as of Q2 2026.

  • Vanguard Capital Management held 9,164 shares of BioAtla worth $37.9K as of Q2 2026.
  • Vanguard Capital Management sold 23,821 BioAtla shares in Q2 2026, an estimated $101K.
  • BioAtla made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #3960 holding.
  • Vanguard Capital Management first reported a position in BioAtla in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Capital Management's BioAtla position peaked at $266K in Q1 2026.
  • 19 funds tracked by Wall St. Rank held BioAtla as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.